Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

NCT00567918 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
52
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Astellas Pharma Inc